M L Berger

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. ncbi request reprint The once and future application of cost-effectiveness analysis
    M L Berger
    Merck and Company, Inc, West Point, PA 19486 0004, USA
    Jt Comm J Qual Improv 25:455-61. 1999
  2. ncbi request reprint Investing in healthy human capital
    Marc L Berger
    USHH Outcomes Research and Management, Merck and Co, Inc, West Point, PA 19486 0004, USA
    J Occup Environ Med 45:1213-25. 2003
  3. ncbi request reprint Efficient patient identification strategies for women with osteoporosis
    T A Abbott
    Outcomes Research and Management, Merk and Co, West Point, PA 19486, USA
    J Clin Densitom 2:223-30. 1999
  4. ncbi request reprint The decision to conduct a head-to-head comparative trial: a game-theoretic analysis
    Edward C Mansley
    Outcomes Research and Management, Merck and Co Inc, WP39 166, P O Box 4, West Point, PA 19486 000, USA
    Med Decis Making 27:364-79. 2007
  5. ncbi request reprint Impact of 3-tier pharmacy benefit design and increased consumer cost-sharing on drug utilization
    Pamela B Landsman
    Outcomes Research and Management, US Medical and Scientific Affairs, Merck and Company Inc, PO Box 100, UG2B 74, 351 N Sumneytown Pike, North Wales, PA 19454 2505, USA
    Am J Manag Care 11:621-8. 2005
  6. ncbi request reprint Evidence synthesis and evidence-based decision making: related but distinct processes
    Steven M Teutsch
    Merck and Co, Inc, West Point, PA 19486, USA
    Med Decis Making 25:487-9. 2005
  7. ncbi request reprint Comparative effectiveness: asking the right questions, choosing the right method
    Steven M Teutsch
    Merck and Company Inc, West Point, Pennsylvania, USA
    Health Aff (Millwood) 24:128-32. 2005
  8. ncbi request reprint Reliability and validity of the Stanford Presenteeism Scale
    Robin S Turpin
    USHH Outcomes Research and Management, Merck and Co, Inc, West Point, Pennsylvania 19486 0004, USA
    J Occup Environ Med 46:1123-33. 2004
  9. ncbi request reprint Asthma control and patient satisfaction among early pediatric users of montelukast
    Siva Narayanan
    Outcomes Research and Management, Merck and Co, Inc, West Point, Pennsylvania 19486, USA
    J Asthma 39:757-65. 2002
  10. ncbi request reprint Cost-effectiveness analysis: from science to application
    Marc L Berger
    Outcomes Research and Management, Merck and Co, Inc, West Point, Pennsylvania 198486, USA
    Med Care 43:49-53. 2005

Collaborators

Detail Information

Publications26

  1. ncbi request reprint The once and future application of cost-effectiveness analysis
    M L Berger
    Merck and Company, Inc, West Point, PA 19486 0004, USA
    Jt Comm J Qual Improv 25:455-61. 1999
    ..However, it must be embedded within a framework that promotes confidence in the social justice of health care decision making through ongoing dialogue about how the value of health and health care are defined...
  2. ncbi request reprint Investing in healthy human capital
    Marc L Berger
    USHH Outcomes Research and Management, Merck and Co, Inc, West Point, PA 19486 0004, USA
    J Occup Environ Med 45:1213-25. 2003
    ..We believe that employers who increase their investments in healthy human capital now will emerge tomorrow as the companies leading the gains in US productivity...
  3. ncbi request reprint Efficient patient identification strategies for women with osteoporosis
    T A Abbott
    Outcomes Research and Management, Merk and Co, West Point, PA 19486, USA
    J Clin Densitom 2:223-30. 1999
    ..In choosing among the efficient strategies, decision makers must determine the extent to which they are willing to trade off higher program cost for greater sensitivity...
  4. ncbi request reprint The decision to conduct a head-to-head comparative trial: a game-theoretic analysis
    Edward C Mansley
    Outcomes Research and Management, Merck and Co Inc, WP39 166, P O Box 4, West Point, PA 19486 000, USA
    Med Decis Making 27:364-79. 2007
    ..Finally, the results indicate that incentives that offset the direct cost of a trial can prevent a no-trial equilibrium, even when both firms face the possibility of an inferior outcome...
  5. ncbi request reprint Impact of 3-tier pharmacy benefit design and increased consumer cost-sharing on drug utilization
    Pamela B Landsman
    Outcomes Research and Management, US Medical and Scientific Affairs, Merck and Company Inc, PO Box 100, UG2B 74, 351 N Sumneytown Pike, North Wales, PA 19454 2505, USA
    Am J Manag Care 11:621-8. 2005
    ..To estimate responsiveness of prescription demand within 9 therapeutic classes to increased cost-sharing compared with constant cost-sharing...
  6. ncbi request reprint Evidence synthesis and evidence-based decision making: related but distinct processes
    Steven M Teutsch
    Merck and Co, Inc, West Point, PA 19486, USA
    Med Decis Making 25:487-9. 2005
  7. ncbi request reprint Comparative effectiveness: asking the right questions, choosing the right method
    Steven M Teutsch
    Merck and Company Inc, West Point, Pennsylvania, USA
    Health Aff (Millwood) 24:128-32. 2005
    ..We consider the consequences of these strategies. This paper proposes a framework for using different methods to assess available evidence. We contend that choosing the appropriate method can occur only when there are clear policy goals...
  8. ncbi request reprint Reliability and validity of the Stanford Presenteeism Scale
    Robin S Turpin
    USHH Outcomes Research and Management, Merck and Co, Inc, West Point, Pennsylvania 19486 0004, USA
    J Occup Environ Med 46:1123-33. 2004
    ..This study reports the reliability and validity of the 13-item Stanford Presenteeism Scale (SPS). The SPS differs from similar scales by focusing on knowledge-based and production-based workers...
  9. ncbi request reprint Asthma control and patient satisfaction among early pediatric users of montelukast
    Siva Narayanan
    Outcomes Research and Management, Merck and Co, Inc, West Point, Pennsylvania 19486, USA
    J Asthma 39:757-65. 2002
    ..To assess asthma control and patient satisfaction among pediatric users of montelukast in a clinical practice setting...
  10. ncbi request reprint Cost-effectiveness analysis: from science to application
    Marc L Berger
    Outcomes Research and Management, Merck and Co, Inc, West Point, Pennsylvania 198486, USA
    Med Care 43:49-53. 2005
    ..Specifically, how should we balance the desires for equity, universal access to healthcare services and technology, and the right of individuals to secure the specific healthcare resources they want?..
  11. ncbi request reprint Alternative valuations of work loss and productivity
    M L Berger
    Department of Outcomes Research and Management, Merck and Co, Inc, 770 Sumneytown Pike WP-39-162, West Point, PA 19486, USA
    J Occup Environ Med 43:18-24. 2001
    ..Finally, we offer an agenda for further research...
  12. ncbi request reprint Growth in use of lipid-lowering therapies: are we targeting the right patients?
    Robert W Dubois
    Zynx Health, Inc, Beverly Hills, California 90212, USA
    Am J Manag Care 8:862-7. 2002
    ..Concern exists that industry marketing has led to increased use of medications by patients with marginal indications...
  13. pmc A randomized controlled open trial of population-based disease and case management in a Medicare Plus Choice health maintenance organization
    David C Martin
    Coventry Health Care, Inc, PA, USA
    Prev Chronic Dis 1:A05. 2004
    ....
  14. ncbi request reprint How to present the business case for healthcare quality to employers
    Sean Nicholson
    Cornell University, Ithaca, New York 14853, USA
    Appl Health Econ Health Policy 4:209-18. 2005
    ....
  15. ncbi request reprint Stanford presenteeism scale: health status and employee productivity
    Cheryl Koopman
    Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA 94305 5718, USA
    J Occup Environ Med 44:14-20. 2002
    ..Further validation of the SPS-6 on actual presenteeism (work loss data) or health status (health risk assessment or utilization data) is needed...
  16. ncbi request reprint Valuing reductions in on-the-job illness: 'presenteeism' from managerial and economic perspectives
    Mark V Pauly
    Health Care Systems Department, The Wharton School, University of Pennsylvania, Philadelphia, PA, USA
    Health Econ 17:469-85. 2008
    ....
  17. ncbi request reprint A general model of the impact of absenteeism on employers and employees
    Mark V Pauly
    Health Care Systems Department, The Wharton School, 3641 Locust Walk, Philadelphia, PA 19104 6218, USA
    Health Econ 11:221-31. 2002
    ..In the long run, workers are likely to bear much of the incidence of the costs associated with absenteeism, and therefore be the likely beneficiaries of any reduction in absenteeism...
  18. ncbi request reprint Caspofungin versus amphotericin B for candidemia: a pharmacoeconomic analysis
    John R Wingard
    University of Florida College of Medicine, Gainesville, 32610, USA
    Clin Ther 27:960-9. 2005
    ..7% and 62.8% of patients, respectively) and exhibited a generally better safety profile, particularly with respect to impaired renal function (IRF) (P = 0.02)...
  19. ncbi request reprint Measuring the effects of work loss on productivity with team production
    Sean Nicholson
    Department of Policy Analysis and Management, Cornell University, Ithaca, NY 14853, USA
    Health Econ 15:111-23. 2006
    ..The median multiplier is 1.28, which supports the view that the cost to the firm of missed work is often greater than the wage...
  20. ncbi request reprint The assessment of chronic health conditions on work performance, absence, and total economic impact for employers
    James J Collins
    The Dow Chemical Company, Midland, Michigan, USA
    J Occup Environ Med 47:547-57. 2005
    ..The objective of this study was to determine the prevalence and estimate total costs for chronic health conditions in the U.S. workforce for the Dow Chemical Company (Dow)...
  21. ncbi request reprint A metaanalysis of severe upper gastrointestinal complications of nonsteroidal antiinflammatory drugs
    Joshua J Ofman
    Southern California Evidence Based Practice Center, Department of Medicine, Cedars Sinai Health System, Beverly Hills 90212, USA
    J Rheumatol 29:804-12. 2002
    ..We synthesized the published and unpublished evidence to determine the least biased estimates of the risks of perforations, ulcers, and bleeds (PUB) associated with NSAID use from all study designs and all languages...
  22. ncbi request reprint Do NSAIDs cause dyspepsia? A meta-analysis evaluating alternative dyspepsia definitions
    Walter L Straus
    AHCPR Southern California Evidence Based Practice Center, Los Angeles, California, USA
    Am J Gastroenterol 97:1951-8. 2002
    ..Using alternative definitions, we assessed the relationship between NSAID use and dyspepsia...
  23. ncbi request reprint Meta-analysis of dyspepsia and nonsteroidal antiinflammatory drugs
    Joshua J Ofman
    Cedars Sinai Health System and Zynx Health Inc, Los Angeles, California 90212, USA
    Arthritis Rheum 49:508-18. 2003
    ..Using published and unpublished data sources, we sought to determine estimates of the risks of dyspepsia associated with NSAIDs...
  24. ncbi request reprint Rational formulary decision making: is drug classification rational?
    Marc L Berger
    Value Health 6:175-6. 2003
  25. pmc Aligning quality for populations and patients: do we know which way to go?
    Erica Ilene Lubetkin
    Department of Community Health and Social Medicine, City University of New York Medical School, New York, NY 10031, USA
    Am J Public Health 93:406-11. 2003
    ..Such a creation would amount to a whole that is stronger than the sum of the component parts...
  26. ncbi request reprint Do disease management programs for patients with coronary heart disease make a difference? Experiences of nine practices
    Mary N Walsh
    Northside Cardiology, Indianapolis, Ind, USA
    Am J Manag Care 8:937-46. 2002
    ..To observe the experience of 9 practice sites in implementing provider-defined disease management programs for coronary heart disease patients...